Overview

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2032-03-23

Target enrollment:

Participant gender:

Summary

This study is designed to assess efficacy and safety of T-DXd adjuvant therapy, with or without radiotherapy, post-surgery in anticancer treatment nave (including neoadjuvant therapy) endometrial cancer with various HER2 expression levels.

Phase:

PHASE3

Details

Lead Sponsor:

Daiichi Sankyo

Collaborator:

AstraZeneca

Treatments:

Drug Therapy
trastuzumab deruxtecan